eligibility_summary
Include: adults 18–75, ECOG 0–1, survival >3 mo, metastatic/recurrent solid tumor lacking standard options, measurable disease and tumor tissue for TIL, >28 d since last therapy, adequate marrow/renal/hepatic/coag, LVEF ≥45%, FEV1 ≥50%, contraception. Exclude: pregnancy, CNS cancer/mets, autoimmune/immunodeficiency (HIV+), active infection (TB, HBV/HCV, syphilis), recent major surgery/trauma or live vaccine, serious CV, thromboembolism, or bleeding, substance abuse, prior cell therapy, investigational drug/other trial <28 d, other cancer <5 y, investigator decision.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
manual_review_required
ai_summary
Trial: Phase 1, single-arm TIL therapy for advanced solid tumors. Interventions: Autologous tumor-infiltrating lymphocyte (TIL) infusion (biologic/cellular therapy), with IL-2 support (cytokine drug). Mechanisms: Patient’s tumor-resident T cells are isolated, expanded, and activated ex vivo, then reinfused to deliver antigen-specific cytotoxicity via TCR recognition of tumor neo/tumor-associated antigens, killing targets through perforin/granzyme release and cytokine secretion. IL-2 promotes T-cell survival, proliferation, and function post-infusion. Cells/pathways targeted: Tumor cells presenting antigens on MHC, TCR signaling, effector CD8+ (and helper CD4+) T-cell activation and clonal expansion, remodeling of the immunosuppressive tumor microenvironment. Outcome focus: safety and efficacy in metastatic/recurrent solid tumors.